CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 61 enrolled
Drug / intervention
MT-6548 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03645863
NCT03645863Phase 3Completed

A Clinical Pharmacological Study to Evaluate the Effects of Iron Supplements on the Pharmacokinetics of MT-6548 in Healthy Male Volunteers

Tanabe Pharma Corporation·interventional·Posted Aug 24, 2018·Updated Apr 6, 2026

In Brief

A Phase 3 clinical trial evaluating MT-6548, Iron supplement A, and 3 other interventions for Healthy. Completed, enrolled 61 participants across 1 site.

Detailed Summary

The objectives of this study are to investigate the pharmacokinetics and safety of MT-6548 co-administered with iron supplements in healthy male volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedAug 24, 2018
Enrollment StartAug 27, 2018
Primary CompletionSep 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.9 years ago

Interventions

MT-6548drug

Oral tablet

Iron supplement Adrug

Oral tablet

Iron supplement Bdrug

Oral tablet

Iron supplement Cdrug

Oral tablet

Iron supplement Ddrug

Oral tablet